Caribou Biosciences (CRBU) Common Equity (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Common Equity data on file, last reported at $102.0 million in Q1 2026.

• On a quarterly basis, Common Equity fell 53.04% year-over-year to $102.0 million in Q1 2026; TTM through Mar 2026 was $102.0 million, a 53.04% decrease from a year earlier, with the FY2025 full-year figure at $122.2 million, down 51.7% from the prior year.
• Common Equity for Q1 2026 stood at $102.0 million, down from $122.2 million in the prior quarter.
• Over the last five years, Common Equity for CRBU reached as high as $398.3 million in Q3 2023 and fell as low as $102.0 million in Q1 2026.
• Historically, Common Equity has averaged $270.4 million across 5 years, with a median of $281.2 million in 2024.
• Across the five-year window, Common Equity jumped 1141.77% in 2022 and tumbled 53.04% in 2026, its largest moves.
• Year by year, Common Equity stood at $300.9 million in 2022, then grew by 22.44% to $368.4 million in 2023, then tumbled by 31.34% to $253.0 million in 2024, then sank by 51.7% to $122.2 million in 2025, then slipped by 16.5% to $102.0 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $102.0 million in Q1 2026, $122.2 million in Q4 2025, and $141.8 million in Q3 2025.